7ACC2 [1472624-85-3]
Katalog-Nummer HY-D0713-5mg
Size : 5mg
Marke : MedChemExpress
Beschreibung |
7ACC2 is a potent monocarboxylate transporter (MCT) inhibitor with an IC50 of 11 nM for inhibition of [14C]-lactate influx. 7ACC2 is also a potent inhibitor of mitochondrial pyruvate transport. 7ACC2 is an anticancer agent through inhibition of lactate flux[1][2]. |
IC50 & Target | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cellular Effect |
|
||||||||||||||||||||
In Vitro |
7ACC2 (compound 19; 72 hours) inhibits SiHa cells proliferation in lactate-containing medium with an EC50 of 0.22 μM. In SiHa cells, lactate uptake primarily depends on the high affinity MCT1 transporter[1]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||||||||||
In Vivo |
7ACC2 (3?mg/kg; intraperitoneal administration; daily; for 5 days or 10days) treatment significantly inhibits tumor growth in mice. 7ACC2 radiosensitizes tumor cells by reducing hypoxia in vivo[2]. MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
|
||||||||||||||||||||
Molekulargewicht |
309.32 |
||||||||||||||||||||
Formel |
C18H15NO4 |
||||||||||||||||||||
CAS. Nr. | |||||||||||||||||||||
Appearance |
Solid |
||||||||||||||||||||
Color |
Light yellow to yellow |
||||||||||||||||||||
SMILES |
CN(C1=CC=C(C=C(C(O)=O)C(O2)=O)C2=C1)CC3=CC=CC=C3 |
||||||||||||||||||||
Versand | Room temperature in continental US; may vary elsewhere. |
||||||||||||||||||||
Speicherung |
4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) |
||||||||||||||||||||
Lösungsmittel & Löslichkeit |
In Vitro:
DMSO : 50 mg/mL (161.64 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) Preparing
Stock Solutions
View the Complete Stock Solution Preparation Table
*
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles. Select the appropriate dissolution method based on your experimental animal and administration route.
For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
|
||||||||||||||||||||
Reinheit & Dokumentation |
Purity: 99.73% |
||||||||||||||||||||
Verweise |
|